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Abstract: The number of adults with congenital heart disease (ACHD) has increased over the last decades 
due to advancements in medical care, including interventional and surgical therapies. We are therefore more 
frequently challenged by the long-term consequences of palliative or corrective surgery carried out during 
childhood. Although patients with ACHD may develop conditions related to general cardiovascular risk 
factors, such as coronary artery disease, the most common complications leading to morbidity and mortality 
are arrhythmias, heart failure and thromboembolic events. For the management of arrhythmias, current 
recommendations regarding ablation and device therapy must be considered, whilst also taking into account 
the anatomical limitations of their congenital heart defect or surgical pathways. Heart failure treatment 
in acute and chronic settings must also consider the particular anatomy present, including the nature of 
the systemic ventricle. Treatments strategies for ACHD are typically extrapolated from the respective 
guidelines in non-ACHD patients, despite a lack of evidence to support this strategy. Right heart failure can 
be especially challenging to manage in conditions where either a systemic right ventricle or shunt lesions 
resulting in volume and/or pressure loading of the right ventricle are present. All physicians and cardiologists 
in particular should be acquainted with the most common diseases in ACHD, their complications and 
management regime, especially with regards to heart failure as this is a common reason for acute presentation 
in the emergency department.
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Introduction
The number of patients with adults with congenital heart 
disease (ACHD) is constantly increasing due to advances 
in the medical and surgical treatment options improving 
the outcome of children with complex congenital heart 
disease (1-4) (Figure 1 regarding epidemiology of ACHD 
patients). Current guidelines and other evidence suggest 
that treatment should be performed by trained physicians 
(1,2,4) with appropriate infrastructure for the specialised 
care for these patients (5-7).
The number of patients with ACHD has increased 
by about 50% compared with the number of children 
with congenital heart defects since the beginning of the 
new millennium (8-11). Currently adult patients account 
for about two thirds of all patients with congenital heart 
disease (12) and this change in demographics is resulting 
in a mortality shift from infancy to adulthood (5,13). 
Patients with complex cardiac disease after palliative or 
corrective surgery can present with the surgical sequelae 
of heart defects (2,4-6,14-16). The most common defects 
resulting in emergency hospitalisation of the patient are 
the univentricular heart, followed by tetralogy of Fallot, 
common arterial trunk, and discordant connections such 
as transposition of the great arteries following Senning or 
Mustard operations and congenitally corrected transposition 
of the great arteries (5,6,14-16). Frequent reasons for 
admittance to the emergency department are arrhythmias, 
as well as heart failure (HF), thromboembolic complications 
resulting in stroke or pulmonary embolism and non-cardiac 
causes (2,4-6,16). 
This manuscript aims to describe the most common 
diseases in detail to elucidate diagnostic, treatment and 
management strategies for patients with ACHD. 
Objectives
This review summarizes the aetiology, diagnostic process 
and treatment of heart failure in ACHD patients. In 
addition, the most recent guidelines were included, 
accomplishing the goal of a better treatment algorithm. 
Further a focus of the review is to give examples of special 
situations which are often encountered in ACHD patients 
presenting with heart failure like treatment with cardiac 
resynchronization therapy or potential treatment with a 
ventricular assist device. We present the following article 
in accordance with the NARRATIVE REVIEW reporting 




A literature search was performed in PubMed covering 
publications up to April 2020. The following combinations 
of keywords were used: heart failure and CHD, morbidity 
and mortality in ACHD, guidelines heart failure and 
ACHD, guidelines diagnostic and treatment of patients 
with congenital heart disease. These search terms had to be 
identified anywhere in the text in the articles. The authors 
as well did choose literature depicting the current guidelines 
or multicenter trials, however most of the literature are 
of observational studies and guidelines for patients with 
ACHD have the evidence level of expert opinion. 
Both qualitative and quantitative studies were considered 
to elucidate the use of the different aspects regarding 
congenital heart disease, anticoagulation and combination 
of both. The search was restricted to original research, 
humans, and papers published in English at any date. 
All abstracts were reviewed to assess whether the article 
met the inclusion criteria. After this selection process, a 
manual search of the reference lists of all eligible articles 
was performed. Two authors (i.e., EZ and CS) assessed 
independently the methodological quality of the qualitative 
and quantitative studies prior to their inclusion in the 
review.
Epidemiology of heart failure (HF) in ACHD
Patients with ACHD and complex cardiac anatomy 
are prone to develop HF over the course of their lives, 
especially those with a univentricular circulation. Signs 
of HF have been reported in about 22% of adults with 
transposition of the great arteries (TGA) following an 
atrial switch (Senning or Mustard operation), 32% of 
adults with congenitally corrected transposition (ccTGA) 
and 40% of adults following Fontan completion (17,18). 
In patients with ACHD, HF is responsible for about 20% 
of mortality, often during early adulthood (19). Current 
clinical guidelines may not be directly applicable to this 
complex cohort of patients due to a lack of evidence 
(18,20,21). For the treatment of patients with ACHD 
who develop HF, it is important to assess if there are 
any residual hemodynamic lesions such as a shunt or 
atrioventricular valve regurgitation (22,23).
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Figure 1 Complexity of congenital heart disease with prevalence of the disease. Prevalence of complex lesions is increasing due to a better 
survival in patients with moderate or complex congenital heart disease. 
Simple complexity
a. lsolated congenital mitral valve 
disease
b. Isolated congenital aortic 
valve disease
c. Atrial septal defect
d. Ventricular septal defect
e. Patent ductus arteriosus
f. Coarctation of the aorta (simple 
lesion)
Moderate complexity
a. Anomalous pulmonary vein 
return (partial or total)
b. Atrioventricular septal defect 
(partial or complete)
C. Coarctation of the aorta 
(complex lesion)
d. Ebstein anomaly
e. Moderate to severe pulmonary 
valve stenosis/regurgitation
f. Sinus venosus defect
g. Subaortic stenosis
h. Stradling mitral or tricuspid 
valve
Increasing morbidity and mortality of the congenital heart defect
Complex lesions
a. All cyanotic heart diseases 





f. Single ventricle physiology
g. Transposition of the great 
arteries
h. Heterotaxy syndromes 
Limitation of exercise capacity in patients with 
ACHD and heart failure
Patients with ACHD often do not present with the same 
symptoms as other patients with HF (17,18,20,24) as they 
have already adapted to living with impaired physical 
exercise tolerance. It is therefore important to gain objective 
evidence from cardiopulmonary exercise testing to detect 
a decline in physical exercise tolerance in order to identify 
patients who may benefit from therapeutic interventions 
and those at risk of an adverse outcome (25,26). Many 
patients with congenital heart defects will have impaired 
peak oxygen consumption, this is due to multiple factors 
including inadequate cardiac reserve, poor heart rate 
response to exercise, raised pulmonary pressures upon 
exercise, poor pre-conditioning, or even due to restrictions 
recommended by physicians. 
Comorbidities and anatomic variations 
predisposing to heart failure
Systemic right ventricle
In patients with TGA following an atrial switch, hypoplastic 
left heart syndrome following the Norwood operation, 
and uncorrected ccTGA, the morphologic right ventricle 
is in the systemic circulation. The morphologic right 
ventricle is a thin-walled structure with only two muscle 
layers, compared with three layers in the morphologic left 
ventricle, and is heavily dependent on loading conditions, 
especially changes in afterload (18,20,22,23); it is therefore 
unable to sustain the pressure generation required to 
pump blood around the systemic circulation and over time 
is predisposed to fail. Additionally for the development 
of heart failure the presence of a trileaflet tricuspid valve 
rather than a bileaflet mitral valve is significant. These 
patients frequently develop tricuspid regurgitation which 
exacerbates heart failure symptoms, especially in Ebstein-
like tricuspid dysplasia, which is the most common cardiac 
abnormality related to ccTGA (22,23,27).
Pulmonary vascular disease
Evaluation of the pulmonary circulation is of paramount 
importance in patients presenting with subpulmonary RV 
failure and those with a Fontan circulation (17,22,23). 
Pulmonary arterial hypertension (PAH) is common 
in ACHD as a result of anatomic heterogeneity and 
requires careful characterisation to target specific medical 
treatments addressing PAH, whilst misclassification can be 
deleterious for patients assessed for heart transplantation 
(17,22). Most patients with ACHD and PAH have WHO 
(World Health Organization) group 1 PAH, with a 
pulmonary vascular resistance (PVR) of ≥3 Wood units. 
Some may have pulmonary hypertension WHO class 
2 with an increased pulmonary wedge pressure, whilst 
others, especially those with TGA or ccTGA, may have 
components of both pre- and postcapillary pulmonary 
hypertension which are most commonly related to WHO 
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class 2 or 5 (17,28). Postcapillary pulmonary hypertension 
can arise due to a failing systemic right ventricle in case 
of ccTGA or TGA after atrial switch procedure and 
precapillary pulmonary arterial hypertension can be 
associated with shunt lesions or abnormalities of the 
pulmonary vasculature (4,17). 
Meticulous assessment of the hemodynamic status 
i s  crucia l  to  determine whether  a  pat ient  would 
require from lung transplantation in addition to heart 
transplantation (17). In patients with ACHD, development 
of pulmonary hypertension is associated with a 2-fold 
increase in all-cause mortality (17).
Shunts, collaterals and baffles
During the assessment of patients with complex CHD, 
it is important to consider the presence or persistence 
of shunts and collaterals as these may cause additional 
volume and/or pressure load. Pre-tricuspid shunt lesions, 
e.g., atrial septal defect, result in volume loading on the 
pulmonary circulation whilst post-tricuspid shunt lesions, 
e.g., ventricular septal defect and patent ductus arteriosus, 
cause volume loading of the left ventricle that may lead to 
a decline in left heart function. In a Fontan circulation, a 
spontaneous or surgically created fenestration may cause 
right-to-left shunting with arterial desaturation (22). 
Patients with TGA after atrial switch procedure show 
an impaired capacitance and conduit function of the 
baffles (29) and so a fast heart rate, such as during atrial 
fibrillation with a fast ventricular response, is not well 
tolerated, with reduced diastolic ventricular filling 
causing decreased cardiac output, that may even lead to 
cardiogenic shock (22,29). The baffles in patients with 
Fontan circulation are prone to narrowing or developing 
stenosis resulting in filling disorders of the single 
ventricle (4).
Heart failure management in ACHD and specific 
considerations
The number of patients with ACHD presenting to the 
emergency department with heart failure symptoms 
increases with the age and survival of the patients 
(9-11,18). Concerning the treatment strategy it has 
implications whether the anatomy of the patients is related 
to a morphologic left or right ventricle in the systemic 
circulation, whether the sub-pulmonary right ventricle is 
impaired, or whether the patient has a Fontan circulation 
(18,30,31). HF in patients with ACHD is often complicated 
by comorbidities resulting from the initial palliative or 
corrective surgical procedure. Frequently impaired renal 
function or haematological disorders with increased 
haematocrit due to chronic systemic cyanosis can be 
observed. In patients with a Fontan circulation, chronically 
elevated pressure in the systemic venous pathways and 
hepatic veins leads to hepatic enlargement, progressive 
fibrosis and even cirrhosis and in some cases hepatocellular 
carcinoma (18).
Diagnosis of HF in patients with ACHD
Knowledge of the underlying congenital heart defect as 
well as the history of previous surgeries and interventions 
is crucial for the diagnosis of HF in ACHD. The change in 
symptoms might be subtle, a common first symptom being 
the onset of arrhythmia (18). Besides the need for a regular 
work-up with ECG and imaging including advanced 
imaging modalities like cardiac magnetic resonance 
imaging or computer tomography, two cornerstones for 
diagnosis are laboratory testing including N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) and 
cardiopulmonary exercise testing (CPET). Two challenges 
for diagnosis are the symptomatic patients with normal 
systemic ventricular function and the asymptomatic patient 
with impaired function of the systemic right ventricle. 
In these two constellations a decrease of peak oxygen 
consumption by 25% in CPET or two-fold increase of 
NT-proBNP during 6 months of follow-up are indicators 
to start treatment (18). 
An important difference to other current HF guidelines 
is the threshold of the ejection fraction being <40% before 
medical treatment is recommended (18). ACHD patients 
with heart failure and an anatomical left ventricle as 
systemic ventricle with a reduced ejection fraction <40% 
are treated with the same medication as recommended 
in non-ACHD patients (18). Most commonly renin-
angiotensin-aldosterone-system blockers are used in 
addition to beta-blockers, mineralocorticoid receptor 
antagonists and diuretics or digoxin. If the failing ventricle 
is an anatomic right ventricle the medication is only 
used in symptomatic patients (18). Patients with a single 
ventricle are handled the same way. These patients are 
treated with the suggested medication if the ventricle is 
an anatomic left ventricle irrespective of symptoms and 
in case of an anatomic right single ventricle only if the 
patient is symptomatic (18). 
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Treatment of HF in ACHD
Patients with impaired function of the systemic left ventricle 
are often treated according to the ESC guidelines on HF 
(18,21). Most commonly the treatment includes therapy 
with an ACE-inhibitor, AT-1 receptor blocker or beta-
blocker, as well as diuretics for symptomatic relief. 
In patients with a systemic morphologic right ventricle, 
HF is likely to develop over time since the anatomy and 
geometry of the right ventricle are not adapted to generate 
the needed perfusion pressure for the systemic circulation 
(18,30). Whilst clear evidence for recommendations is 
lacking, asymptomatic patients with a failing systemic right 
ventricle are often treated with beta-blockers. However, 
symptomatic patients are treated analogous to patients with a 
failing morphologic left ventricle (18). If the sub-pulmonary 
morphologic left or right ventricle is compromised, no 
treatment is recommended in asymptomatic patients, but in 
the presence of symptoms, a combination of diuretics can 
provide symptomatic relief (18).
For patients with a functionally univentricular heart 
who have been palliated with a Fontan circulation, the 
presence of HF symptoms in conjunction with impaired 
ventricular function indicates the need for treatment and 
symptom relief, with no difference in approach to those 
with a systemic morphologic left or right ventricle (18). 
The largest benefits have been reported from reducing 
pulmonary vascular resistance with specific therapy such 
as phosphodiesterase inhibitors, or reducing afterload with 
beta blockers, whilst diuretics are only recommended if 
fluid overload is present (18).
Treatment of acute heart failure in patients with ACHD
Currently there are no specific guidelines for the treatment 
of patients with ACHD and acute heart failure (AHF), 
hence treatment recommendations are based on those for 
the general heart failure population, with a specific focus 
on comorbidities or anatomic variations present. Patients 
with ACHD and advanced HF may also be considered for 
ECMO therapy or ventricular assist device therapy as a 
bridge to destination therapy, if available and appropriate 
(18,21-23).
Heart failure therapy in patients with ACHD needs to 
take into account the individual anatomic circumstances 
and frequent comorbidities complicating therapy for an 
individual patient. Optimal outcomes are achieved when 
these patients are managed by specialist ACHD teams 
(17,24). 
Device treatment with intra-cardiac cardioverter 
defibrillator (ICD) in patients with ACHD and heart 
failure
Evidence for the use of an ICD in patients with ACHD 
is limited and is frequently based on expert opinion as the 
most commonly derived data on ICD use in ACHD is from 
observational studies (4,32-34). In general, the indications 
as outlined in the current ESC guidelines regarding ICD 
indications for secondary prevention can be extrapolated to 
ACHD (32-34). Patients with repaired tetralogy of Fallot, 
TGA following atrial switch, and uncorrected ccTGA are 
reported to have a high incidence of ventricular arrhythmias 
and are often candidates for ICD implantation in the 
context of secondary prevention (32-34). Regarding primary 
prevention, guidelines concur that patients with ACHD 
fulfilling the current ICD criteria with a left ventricular 
ejection fraction <35%, biventricular physiology, optimally 
treated heart failure, and NYHA symptom class II or III, 
are candidates for ICD implantation (32-34). However, 
appropriate selection of candidates remains challenging, 
weighing the benefits against the potential risks of infection 
or venous obstruction due to intravascular lead placement 
(32-34) as well as the potential technical challenges posed in 
patients with complex anatomy.
Cardiac resynchronization therapy (CRT) in patients with 
ACHD
The efficacy of CRT varies in patients with ACHD 
according to the underlying disease and anatomic 
substrate and whether a systemic morphologic left, right 
or functionally univentricular heart is present (32,34). 
Whilst reported data in ACHD is mostly derived from 
observational studies, CRT has a class I indication in 
patients with a systemic morphologic left ventricle and who 
fulfil the same indication criteria for CRT as non-ACHD 
patients (34,35). However, even if the systemic ventricle is a 
morphologic right ventricle, CRT can be considered if the 
ejection fraction is <35%, the ventricle is dilated, the patient 
displays NYHA class II to IV (ambulatory) symptoms, and 
a complete right bundle branch block with a QRS complex 
≥150 msec is present (34,35). An additional important 
potential indication for CRT in patients with ACHD is 
the presence of a pacing threshold >40% during exchange 
of a pre-existing device or if a high pacing threshold is 
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anticipated (34,35). Reports of patients with ACHD who 
are potential candidates for heart transplantation improving 
their functional status after CRT implantation to the extent 
that they can be removed from the transplant waiting list, 
suggests that CRT indications should be reviewed in the 
ACHD population (34,35).
Ventricular assist devices: special 
considerations in patients with ACHD
Considering the rising number of patients with ACHD 
and the increase in HF in this population, there is a need 
to evaluate additional treatment options. Among the novel 
therapies developed for HF, durable mechanical circulatory 
support in the form of ventricular assist devices (VADs) can 
function as a bridge to transplantation. These devices have 
been shown to decrease mortality in end-stage HF among 
non-transplant candidates and appear to offer a similar 
benefit to transplant candidates who are deteriorating whilst 
awaiting transplantation (21,36). For VAD implantation, 
patients should be considered according to whether they 
have a systemic morphologic left or right ventricle or a 
functionally univentricular heart. In the largest study to 
date, more patients with ACHD required biventricular 
ventricular assist or a total artificial heart than non-ACHD 
patients, and they more often had concomitant dysfunction 
of the subpulmonary ventricle (either morphologic left or 
right ventricle) and pulmonary hypertension than their 
non-ACHD counterparts (36). Patients with ACHD had 
higher rates of mortality and adverse events than non-
ACHD patients in the study, but the increased mortality 
rate was attributable solely to the higher use of biventricular 
ventricular assist devices and total artificial hearts. 
Conversely, the two groups who had VAD implantation to 
support the systemic ventricle alone, demonstrated similar 
survival regardless of cardiac anatomy (36).
Heart transplantation in patients with ACHD
In advanced HF, listing for heart transplantation is the 
ultimate option for disease management (21). However, 
patients with ACHD frequently have numerous adverse 
features including pulmonary arterial hypertension and 
other advanced organ involvement, such as liver disease in 
patients with Fontan circulation, resulting in a high waiting 
list mortality (17,37). Patients removed from the waiting list 
have an especially poor prognosis as they cannot be bridged 
to transplantation with a VAD or have severe HF with 
multi-organ failure most commonly involving the liver and/
or kidneys (37,38). During transplant assessment in patients 
with ACHD, a comprehensive anatomic and hemodynamic 
assessment is warranted to identify potentially correctable 
residual lesions from the original congenital heart defect 
and subsequent surgical or catheter procedures (17). 
Patients with moderate or complex congenital heart 
disease are closely screened and potential candidates for 
transplantation can be identified early, before multi-organ 
involvement prohibits potential listing. Until the definition 
of clear guidelines for the management of these patients, 
they should be screened especially carefully at a centre 
familiar with transplantation in congenital heart disease 
(4,18).
Summary
Heart failure is one of the most common causes of 
death in the increasing number of patients with ACHD. 
These patients frequently have impaired function of 
the cardiovascular system, but often do not present 
early because they have adapted to living with impaired 
function from childhood. Thus rigorous follow-up of 
patients with ACHD is necessary, especially for those who 
have had palliative surgery or with underlying complex 
lesions. Current guidelines support the use of imaging, 
cardiopulmonary exercise testing and biomarkers as key 
investigations in disease progression monitoring. Treatment 
is based on the extrapolation of current knowledge 
from acquired heart disease in patients with systemic 
left ventricular dysfunction, even though the stabilising 
or beneficial effect of these medications is yet to be 
demonstrated in patients with ACHD. In advanced heart 
failure, hemodynamic assessment is essential to identify 
patients who may be candidates for heart transplantation. In 
those who are not suitable for listing for transplantation or 
with precluding comorbidities, a durable ventricular assist 
device should be considered whilst taking into account that 
only patients with singular VAD for the systemic ventricle 
had an outcome comparable to non-ACHD patients. 
Whilst heart failure is frequently encountered in patients 
with ACHD and several treatment options are available, it 
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